Members Login
Channels
Special Offers & Promotions
New Application Note: COVID-19 agent molnupiravir
Molnupiravir (Lagevrio®) is an antiviral medication to treat mild to medium COVID-19 infection.
Molnupiravir is actually a prodrug of the active substrate N4-hydroxycytidine (NHC), a synthetic ribonucleoside analogue. The treatment leads to the introduction of copying errors during viral RNA replication and by this inhibits the viral reproduction.
This new Application Note demonstrates how molnupiravir and its active agent β-d-N4-hydroxycytidine can be separated by using a YMC-Triart C18 UHPLC column and a MS compatible mobile phase at pH 4.3 and relatively mild temperature of 40°C.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.
Media Partners